Geron Corporation to Present at Lazard Capital Markets Healthcare Conference
MENLO PARK, Calif., November 18, 2008 - Geron Corporation (Nasdaq: GERN) today announced that Thomas B. Okarma, Ph.D., M.D., president and chief executive officer, will present an update of the company's oncology programs at 3:00 p.m. ET on Wednesday, November 19, 2008, at the Lazard Capital Markets 5th Annual Healthcare Conference in New York City.
The update will focus on Geron's portfolio of anti-cancer therapies, including the telomerase inhibitor drug (GRN163L) and the telomerase therapeutic vaccine (GRNVAC1). The presentation will also include information on the company's development program for its second generation cancer vaccine (GRNVAC2) based on human embryonic stem cells.
An audio and slide webcast of the presentation will be available at the following website address: http://www.wsw.com/webcast/lz5/gern/. The replay will be available approximately 24 hours after the presentation and will be accessible for a period of 30 days.
About Geron
Geron is a biopharmaceutical company that is developing first-in-class therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. The products are based on our core expertise in telomerase and human embryonic stem cells. For more information, visit www.geron.com.
CONTACT:
Anna Krassowska Investor and Media Relations 650-473-7765 info@geron.com
